Therapeutics

Tools

Back to the Top
Search By Attributes

Search Results

Name Synonyms FDA Status Company Target Type Therapy Type Approved
For
RO7105705 MTAU9937A,
RG6100
Alzheimer's Disease (Phase 2) AC Immune SA, Genentech, Hoffmann-La Roche Tau Immunotherapy (passive)
BIIB092 BMS-986168, IPN007 Progressive Supranuclear Palsy (Phase 2), Alzheimer's Disease (Phase 2) Biogen, Bristol-Myers Squibb Tau Immunotherapy (passive)
C2N 8E12 ABBV-8E12 Progressive Supranuclear Palsy (Phase 2), Alzheimer's Disease (Phase 2) AbbVie, C2N Diagnostics, LLC Tau Immunotherapy (passive)
Crenezumab MABT5102A ,
RG7412
Alzheimer's Disease (Phase 2) AC Immune SA, Genentech, Hoffmann-La Roche Amyloid-Related Immunotherapy (passive) None
Donanemab N3pG-Aβ Monoclonal Antibody,
LY3002813
Alzheimer's Disease (Phase 2) Eli Lilly & Co. Amyloid-Related Immunotherapy (passive)
Etanercept Enbrel™ Alzheimer's Disease (Phase 2) Amgen, Inc., Pfizer Inflammation Immunotherapy (passive) Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondilysis
LY3303560 Alzheimer's Disease (Phase 2) Eli Lilly & Co. Tau, Unknown Immunotherapy (passive)